TLN-372 in Advanced KRAS Mutant Solid Tumors

ClinicalTrials.gov ID: NCT07204340

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07204340. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Study identification

NCT ID: NCT07204340
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Treeline Biosciences, Inc.; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

KRAS Mutant Solid Tumors

Interventions

TLN-372 Drug
TLN-372 in combination with cetuximab Drug
TLN-372 in combination with pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2025 (Actual)
Primary completion: Dec 3, 2031 (Estimated)
Completion: Apr 1, 2032 (Estimated)
Last update posted: Jul 28, 2026

2025 – 2032

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215-5450	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
Washington University Medical Campus	St Louis	Missouri	63108	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021-3402	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07204340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 28, 2026 · Synced Nov 15, 2026